Your session is about to expire
← Back to Search
Lenalidomide + Vaccine for Chronic Lymphocytic Leukemia
Study Summary
This trial studies the effect of lenalidomide and vaccine therapy in treating patients with early-stage asymptomatic chronic lymphocytic leukemia or small lymphocytic lymphoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have received treatment for my CLL/SLL before this study.I haven't taken corticosteroids in the last two weeks, except for a non-cancer related condition.I do not meet the criteria for starting treatment based on symptoms or previous therapies for CLL/SLL.I do not have a recent DVT/PE, severe allergies, other cancers, serious illnesses, and I'm not pregnant or breastfeeding. I don't have HIV, autoimmune issues, erythema nodosum, and I'm not on H2-blockers.I have been diagnosed with CLL or SLL according to WHO standards.My CLL/SLL cancer cells show high-risk genetic changes.I meet the standard treatment criteria for CLL/SLL.
- Group 1: Arm A (Concurrent PCV13 and lenalidomide)
- Group 2: Arm B (Sequential PCV13 and lenalidomide)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What do healthcare professionals usually employ Pneumococcal Polyvalent Vaccine to address?
"Pneumococcal Polyvalent Vaccine is frequently administered to individuals who have received at least two prior courses of systemic chemotherapy. Furthermore, this vaccine has demonstrated efficacy in treating patients with multiple myeloma and follicular lymphoma that had been previously treated."
Has the Pneumococcal Polyvalent Vaccine been accredited by the FDA?
"Our researchers at Power rate the safety of Pneumococcal Polyvalent Vaccine a 2 due to the absence of efficacy data, which is typical for phase 2 trials."
How many participants is this research project accommodating?
"This clinical trial is no longer accepting patients. It was initially posted on September 8th 2011, with the last edit made to it occurring July 27th 2022. However, there are still 2865 trials open for enrolment that involve antilymphocyte immunoglobulin and a further 287 studies actively recruiting patients who require Pneumococcal Polyvalent Vaccine treatment."
Could you provide an overview of the past experiments with Pneumococcal Polyvalent Vaccine?
"At this moment, there are 287 studies being conducted on Pneumococcal Polyvalent Vaccine; 60 of which have advanced to the third phase. While most trials take place in Mishawaka, Indiana, a total of 13542 locations host relevant clinical research for this therapy."
Is enrollment in this research program still open?
"Clinicaltrials.gov reports that this investigation, which first appeared on the platform in September 2011 and last updated July 2022, is not accepting new patients at present. Nevertheless, there are still 3152 other medical trials actively recruiting participants."
Who is the ideal candidate for enrollment in this research project?
"This clinical trial is recruiting 48 individuals who are 18 to 79 years old and have antilymphocyte immunoglobulin. Other prerequisites include: palpable splenomegaly or lymphadenopathy, a histologically-verified diagnosis of CLL/SLL, fluorescent in-situ hybridization indicating deletion (17p13.1) on > 20% of cells, complex karyotype (>3 cytogenetic abnormalities), unmutated IgVH sequence homology at >= 98%, progressive leukocytosis with WBC count over 300k/uL, anemia (<11 g/dL) or th"
Is the age limit set for this investigation confined to participants under 25 years of age?
"The requirements for joining this medical trial stipulate that patients must be at least 18 years old and no older than 79."
Share this study with friends
Copy Link
Messenger